<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233814</url>
  </required_header>
  <id_info>
    <org_study_id>LTI-03-1001</org_study_id>
    <nct_id>NCT04233814</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose &amp; Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate the initial safety, tolerability, and PK profile of&#xD;
      inhaled LTI-03 in healthy volunteers. In order to minimize exposure, the study will first&#xD;
      test single ascending doses (SAD) of LTI-03 followed by multiple ascending dose (MAD)&#xD;
      cohorts.&#xD;
&#xD;
      Findings from this study will direct the clinical development of LTI-03 for the treatment of&#xD;
      IPF&#xD;
&#xD;
      The study subject population will include normal healthy male and female volunteers between&#xD;
      18 and 55 years of age (inclusive).&#xD;
&#xD;
      Consistent with other trials involving inhaled medication, subjects must have normal&#xD;
      pulmonary function at Screening and will be excluded if they have a history of active or&#xD;
      recurring allergies, asthma, chronic obstructive pulmonary disease (COPD), chronic sinus&#xD;
      drainage, chronic or acute cough or other respiratory condition deemed exclusionary by the&#xD;
      Investigator. History of liver dysfunction or elevated bilirubin, alanine aminotransferase&#xD;
      (ALT) or aspartate aminotransferase (AST) values at Screening will also be grounds for&#xD;
      exclusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The first part of the study will follow a Single Ascending Dose design. Subjects receive a single dose of double-blind study medication (investigational medicinal product LTI-03 or placebo) on Day 1.&#xD;
For each dose level cohort, two eligible sentinel subjects will be randomized in a 1:1 ratio to receive active:placebo study medication.&#xD;
If no tolerability issues are observed by the Investigator within 48 hours post-dose, dosing will commence for the remaining six subjects in the cohort, who will be randomized in a 5:1 ratio to receive active:placebo study medication.&#xD;
The second part of the study will follow a Multiple Ascending Dose design. Subjects receive double-blind study medication (LTI-03 or placebo) once-daily from Day 1 to Day 14.&#xD;
For each dose level cohort, eight eligible subjects will be randomized in a 6:2 ratio to receive active:placebo study medication.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The Sponsor, Investigator, and study personnel working on behalf of the Investigator and Sponsor will remain blinded.&#xD;
Study medication will be dispensed by unblinded pharmacy staff to study staff in a blinded manner. Other than the pharmacist(s), all study staff will remain blinded to study medication assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>up to 49 days</time_frame>
    <description>Incidence of TEAE by system-organ class and dose group as assessed by the Toxicity Grading Scale for Healthy Adult Volunteers</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 20 mg delivered qd x 1 day via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 40 mg delivered qd x 1 day via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 80 mg delivered qd x 1 day via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 dose at 20mg once daily x 14 days via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 dose at 40mg once daily x 14 days via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 dose at 2.5 mg once daily x 14 days via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 dose at 5 mg once daily x 14 days via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTI-03 dose at 5 mg twice daily x 14 days via DPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)</intervention_name>
    <description>LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>MAD Cohort 4</arm_group_label>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-smoker (no use of tobacco products within 6 months prior to dosing) with a&#xD;
             negative urine cotinine test at Screening or Day -1&#xD;
&#xD;
          2. Age of 18-55 years (inclusive)&#xD;
&#xD;
          3. Body mass index (BMI) of 18 - 30.5 kg/m2 (inclusive)&#xD;
&#xD;
          4. Body weight &gt; 50 kg&#xD;
&#xD;
          5. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of asthma&#xD;
&#xD;
          2. Presence of active or recurring allergies, asthma, chronic obstructive pulmonary&#xD;
             disease (COPD), chronic sinus drainage, chronic or acute cough or other respiratory&#xD;
             condition deemed exclusionary by the Investigator or designee&#xD;
&#xD;
          3. Pulmonary infiltrate or pneumonia within 6 months prior to dosing or acute infection&#xD;
             within 14 days prior to dosing&#xD;
&#xD;
          4. History of significant allergy or anaphylaxis&#xD;
&#xD;
          5. Any clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal,&#xD;
             cardiovascular, hepatic, psychiatric, neurologic or allergic disease (excluding hay&#xD;
             fever), as determined by the Investigator or designee&#xD;
&#xD;
          6. Any current clinically relevant abnormalities identified by a detailed medical&#xD;
             history, complete physical examination including blood pressure and heart rate&#xD;
             measurement, and clinical laboratory tests (hematology, coagulation, urinalysis,&#xD;
             clinical chemistries) at Screening or Day -1, as determined by the Investigator or&#xD;
             designee&#xD;
&#xD;
          7. Any clinically significant illness and/or surgery within 28 days prior to dosing&#xD;
&#xD;
          8. Febrile illness within 7 days prior to dosing&#xD;
&#xD;
          9. Weight loss &gt; 5 kg within 28 days prior to dosing&#xD;
&#xD;
         10. Clinically significant 12-lead electrocardiogram (ECG) abnormalities or vital sign&#xD;
             abnormalities (systolic blood pressure &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood&#xD;
             pressure &lt; 50 mmHg or &gt; 90 mmHg, or heart rate &lt; 45 beats per minute [bpm] or &gt; 100&#xD;
             bpm) at Screening or Day -1, as determined by the Investigator or designee&#xD;
&#xD;
         11. History of, or existing severe, acute, chronic, and/or psychiatric medical&#xD;
             condition(s), laboratory abnormality, or other medical concerns that may increase the&#xD;
             risk associated with study participation or IMP administration which, in the judgment&#xD;
             of the Investigator, would make the subject inappropriate for entry into the study&#xD;
&#xD;
         12. History of cancer with the exception of adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
         13. Hemoglobin &lt; lower limit of normal (LLN)&#xD;
&#xD;
         14. Abnormal liver function- alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) &gt; 2 times the upper limit of the normal range (ULN)&#xD;
&#xD;
             - total bilirubin &gt; 1.5 times ULN&#xD;
&#xD;
         15. Abnormal renal function: estimated glomerular filtration rate (eGFR) (modification of&#xD;
             diet and renal disease [MDRD]) &lt; 55 mL/min/1.73 m2&#xD;
&#xD;
         16. Pulmonary function outside the normal range, including forced expiratory volume 1&#xD;
             (FEV1), forced vital capacity (FVC) each &lt; 80% of predicted or FEV1/FVC ratio of ≤ 0.7&#xD;
             at Screening&#xD;
&#xD;
         17. Inability to use study inhaler device appropriately.&#xD;
&#xD;
         18. Positive test results for human immunodeficiency virus (HIV) HIV-1/HIV-2 antibodies,&#xD;
             hepatitis B surface antigen (HBsAG) or hepatitis C virus antibody (HCV-AB) Concurrent&#xD;
             Intake of Other Substances&#xD;
&#xD;
         19. History of alcohol abuse within one year prior to Screening or regular use of alcohol&#xD;
             of ≥ 14 units of alcohol per week for females and ≥ 21 units of alcohol for males (1&#xD;
             unit = 150 mL wine, 360 mL beer or 45 mL of 40% alcohol) within 6 months prior to&#xD;
             dosing or a positive urine alcohol test at Screening or Day -1&#xD;
&#xD;
         20. History of drug abuse or misuse within 5 years prior to dosing or a positive urine&#xD;
             drug test at Screening or Day -1&#xD;
&#xD;
         21. Inability or unwillingness to abstain from alcohol or any drug of abuse for 48 hours&#xD;
             prior to the first dose until completion of the Day 8 visit for the SAD and Day 21&#xD;
             visit for the MAD&#xD;
&#xD;
         22. Exposure to any live vaccines within 28 days prior to dosing&#xD;
&#xD;
         23. Treatment with an investigational product within 30 days or 5 half-lives (whichever is&#xD;
             longer) prior to dosing&#xD;
&#xD;
         24. Use of prescription or non-prescription medications and dietary supplements within 14&#xD;
             days or 5 half-lives (whichever is longer) prior to the first dose of study&#xD;
             medication. Herbal supplements must be discontinued 28 days prior to dosing. Approved&#xD;
             medications taken for contraception are permitted.&#xD;
&#xD;
         25. Positive serum pregnancy test in female subjects&#xD;
&#xD;
         26. Female subjects who are lactating&#xD;
&#xD;
         27. Female subjects of childbearing potential (FOCBP) and men with partners of&#xD;
             childbearing potential who do not agree to use an acceptable form of contraception for&#xD;
             the duration of study treatment and for at least 90 days after the last dose of study&#xD;
             medication. Male subjects who do not agree to refrain from donating sperm during this&#xD;
             same period.&#xD;
&#xD;
         28. Not eligible to receive study medication within 2 weeks of receiving a COVID-19&#xD;
             vaccination, including an initial, second, or booster injection.&#xD;
&#xD;
        NOTE: Female who is surgically sterile or post-menopausal for at least 12 months with&#xD;
        follicle stimulating hormone (FSH) &gt; 30 mIU/ml, are not considered to be of childbearing&#xD;
        potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devinda Weeraratne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Emery, MSPH</last_name>
    <phone>3039026306</phone>
    <email>lemery@lungtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Kinney, MSPH</last_name>
    <phone>7204704743</phone>
    <email>akinney@lungtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Taylor-Holmes</last_name>
      <email>grace.taylor-holmes@celerion.com</email>
    </contact>
    <contact_backup>
      <last_name>Jemma Morrison</last_name>
      <phone>+44 0 28 90 554067</phone>
      <email>jemma.morrison@celerion.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

